A Dose-Effect Study of Cisplatin Ototoxicity in Albino Guinea Pigs

Document Type : Original


1 Department of Audiology, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.

2 School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.

3 Neuroscience Research Center and Department of Physiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Cisplatin is one of the most commonly used antineoplastic drugs; nonetheless, its ototoxic dose-limiting side effects have remained a significant challenge in clinical practice. The recognition of the exact template of hearing loss induced by multiple low doses of cisplatin could be of great help in managing the treatment process. The present study aimed to investigate the effects of multiple doses of this drug on the auditory system.

Material and Methods:
The present study was performed using an experimental guinea pig model in four groups as follows:
1- 0.9% sodium chloride solution, 2- total dose of 7.5 mg/kg Cisplatin, 3- total dose of 10 mg/kg Cisplatin, and 4- total dose of 12.5 mg/kg cisplatin. The drugs were injected as 2.5 mg/kg/daily IP access in all groups. The auditory brainstem response (ABR) test was performed before the treatment and after every injection on a daily basis up to 72 h after the last injection.

There was dose-dependent significant hearing loss in all evaluated frequencies in three cisplatin groups. The general template of induced hearing loss during experimental days was almost the same in groups Cis7.5 and Cis10. In Cis 12.5 group, there was a jump in the threshold shift on the 5th day of the experiment and an upward trend in the function.
As evidenced by the obtained results, the monitoring of hearing loss after every injection in patients who receive the drug and detecting the exact dose-dependent pattern of the induced hearing loss is of great help in controlling its undesirable destructive side effects on the auditory system.


  1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205(4972):698.
  2. Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222(5191): 385.
  3. Einhorn LH. Curing metastatic testicular cancer. Proceedings of the National Academy of Sciences. 2002;99(7):4592-5.
  4. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hearing research. 2007; 226(1-2):157-67.
  5. Slattery EL, Oshima K, Heller S, Warchol ME. Cisplatin exposure damages resident stem cells of the mammalian inner ear. Developmental Dynamics. 2014;243(10):1328-37.
  6. Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. Journal of Clinical Oncology. 2012;30(19):2408.
  7. Skinner R, Pearson A, English M, Price L, Wyllie R, Coulthard M, et al. Cisplatin dose rate as a risk factor for nephrotoxicity in children. British journal of cancer. 1998;77(10):1677.
  8. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Molecular cancer therapeutics. 2009;8(1):10-6.
  9. Devarajan P, Savoca M, Castaneda MP, Park MS, Esteban-Cruciani N, Kalinec G, et al. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hearing research. 2002;174(1-2):45-54.
  10. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacology & toxicology. 1995;76(6):386-94.
  11. Al-Khatib T, Cohen N, Carret A-S, Daniel S. Cisplatinum ototoxicity in children, long-term follow up. International journal of pediatric otorhinolaryngology. 2010;74(8):913-9.
  12. Kolinsky DC, Hayashi SS, Karzon R, Mao J, Hayashi RJ. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. Journal of pediatric hematology/oncology.2010;32(2):
  13. Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. Journal of Clinical Oncology. 2005; 23(34):8588-96.
  14. Mohr PE, Feldman JJ, Dunbar JL, McConkey-Robbins A, Niparko JK, Rittenhouse RK, et al. The societal costs of severe to profound hearing loss in the United States. International journal of technology assessment in health care. 2000;16(04): 1120-35.
  15. Hyppolito MA, Oliveira AAd, Lessa RM, Rossato M. Amifostine otoprotection to cisplatin ototoxicity: a guinea pig study using otoacoustic emission distortion products (DPOEA) and scanning electron microscopy. Revista Brasileira de Otorrinolaringologia. 2005;71(3):268-73.
  16. Wu YJ, Muldoon LL, Neuwelt EA. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. Journal of Pharmacology and Experimental Therapeutics. 2005;312(2):424-31.
  17. Choe W-T, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otology & Neurotology. 2004;25(6):910-5.
  18. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatric hematology and oncology. 2005;22(5):441-5.
  19. Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008;26(22):3749.
  20. McFadden SL, Ding D, Salvemini D, Salvi RJ. M40403, a superoxide dismutase mimetic, protects cochlear hair cells from gentamicin, but not cisplatin toxicity. Toxicology and applied pharmacology. 2003;186(1):46-54.
  21. Wang J, Ladrech S, Pujol R, Brabet P, Van De Water TR, Puel J-L. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Research. 2004;64(24):9217-24.
  22. Cooper LB, Chan DK, Roediger FC, Shaffer BR, Fraser JF, Musatov S, et al. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otology & Neurotology. 2006;27(4):484-90.
  23. So H, Kim H, Lee J-H, Park C, Kim Y, Kim E, et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-κB. Journal of the Association for Research in Otolaryngology. 2007;8(3):338-55.
  24. Li G, Frenz DA, Brahmblatt S, Feghali JG, Ruben RJ, Berggren D, et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology. 2001;22(2):163-76.
  25. Boven E, Verschraagen M, Hulscher T, Erkelens C, Hausheer F, Pinedo H, et al. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. European Journal of Cancer. 2002;38(8):1148-56.
  26. Rybak L, Ramkumar V. Ototoxicity. Kidney international. 2007;72(8):931-5.
  27. Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. International journal of pediatric otorhinolaryngology. 2001;59(1):47-57.
  28. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Otology & Neurotology. 2000;21(4):513-20.
  29. Kizilay A, Kalcioglu M, Ozerol E, Iraz M, Gulec M, Akyol O, et al. Caffeic acid phenethyl ester ameliorated ototoxicity induced by cisplatin in rats. Journal of chemotherapy. 2004;16(4):381-7.
  30. Van Ruijven MW, de Groot JC, Hendriksen F, Smoorenburg GF. Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs. Hearing research. 2005;203(1-2):112-21.
  31. Watanabe K-i, Hess A, Bloch W, Michel O. Nitric oxide synthase inhibitor suppresses the ototoxic side effect of cisplatin in guinea pigs. Anti-Cancer Drugs. 2000;11(5):401-6.
  32. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin‐associated ototoxicity in pediatric oncology patients. Pediatric blood & cancer. 2012;59(1):144-8.
  33. Liba B, Naples J, Bezyk E, Campbell C, Mei M, Parham K. Changes in serum prestin concentration after exposure to cisplatin. Otology & Neurotology. 2017;38(10):e501-e5.
  34. Xiong M, He Q, Wang J, Lai H. Astragalosides reduce cisplatin ototoxicity in guinea pigs. ORL. 2011;73(3):131-6.
  35. Murphy D, Daniel SJ. Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model. Otolaryngology–Head and Neck Surgery. 2011;145(3):452-7.
  36. Waissbluth S, Dupuis I, Daniel SJ. Protective effect of erdosteine against cisplatin-induced ototoxicity in a guinea pig model. Otolaryngology--Head and Neck Surgery. 2012;146(4):627-32.
  37. Laurell G, Engström B. The ototoxic effect of cisplatin on guinea pigs in relation to dosage. Hearing research. 1989;38(1-2):27-33.
  38. Laurell G, Viberg A, Teixeira M, Sterkers O, Ferrary E. Blood-perilymph barrier and ototoxicity: an in vivo study in the rat. Acta oto-laryngologica. 2000;120(7):796-803.